Effect of pretreatment renal function on treatment and clinical outcomes in the adjuvant treatment of older women with breast cancer: Alliance A171201, an ancillary study of CALGB/CTSU 49907

Journal of Clinical Oncology

Volumn 34, Issue 7, 2016, Pages 699-705

  Lichtman, Stuart M ^a   Cirrincione, Constance T ^b   Hurria, Arti ^e   Jatoi, Aminah ^f   Theodoulou, Maria ^a   Wolff, Antonio C ^g   Gralow, Julie ^h   Morganstern, Daniel E ⁱ   Magrinat, Gustav ^c   Cohen, Harvey Jay ^b   Muss, Hyman B ^d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b DUKE UNIVERSITY   (United States)

^c Department of Neonatology   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f MAYO CLINIC   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h SEATTLE CANCER CARE ALLIANCE   (United States)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CREATININE; TAMOXIFEN;

AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLEARANCE; CREATININE CLEARANCE; DRUG ERUPTION; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; BREAST NEOPLASMS; CHEMICALLY INDUCED; KIDNEY FAILURE; KIDNEY FUNCTION TEST; PATHOPHYSIOLOGY; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; URINE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CAPECITABINE; CREATININE; CYCLOPHOSPHAMIDE; FEMALE; FLUOROURACIL; HUMANS; KIDNEY FUNCTION TESTS; METHOTREXATE; PROGNOSIS; RENAL INSUFFICIENCY; SURVIVAL RATE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84964374784     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.62.6341     Document Type: Article

References (28)

1. Launay-Vacher V, Izzedine H, Rey JB, et al: Incidence of renal insufficiency in cancer patients and evaluation of information available on the use of anticancer drugs in renally impaired patients. Med Sci Monit 10: CR209-CR212, 2004
2. Lichtman SM, Wildiers H, Launay-Vacher V, et al: International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 43:14-34, 2007
3. Launay-Vacher V, Chatelut E, Lichtman SM, et al; International Society of Geriatric Oncology: Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol 18:1314-1321, 2007
4. Launay-Vacher V, Oudard S, Janus N, et al; Renal Insufficiency and Cancer Medications (IRMA) Study Group: Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: The Renal Insufficiency and Anticancer Medications (IRMA) study. Cancer 110:1376-1384, 2007
5. Launay-Vacher V, Spano JP, Janus N, et al; Renal Insufficiency and Anticancer Medications (IRMA) Study Group: Renal insufficiency and anticancer drugs in elderly cancer patients: A subgroup analysis of the IRMA study. Crit Rev Oncol Hematol 70:124-133, 2009
6. Muss HB, Berry DA, Cirrincione CT, et al; CALGB Investigators: Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 360:2055-2065, 2009
7. [Erratum: N Engl J Med 361:1714, 2009]
8. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
9. National Kidney Foundation: KDOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. http://www2. kidney.org/professionals/KDOQI/guidelines-ckd/toc.htm
10. National Cancer Institute: Cancer therapy evaluation program: Common toxicity criteria manual, version 2.0. http://ctep. cancer.gov/protocolDevelopment/electronic-applications/docs/ctcmanual-v4-10-4-99.pdf
11. Launay-Vacher V, Gligorov J, Le Tourneau C, et al: Renal Insufficiency and Anticancer Medications (IRMA) Study Group: Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues. Breast Cancer Res Treat 124:745-753, 2010
12. Yoshida H, Goto M, Honda A, et al: Pharmacokinetics of doxorubicin and its active metabolite in patients with normal renal function and in patients on hemodialysis. Cancer Chemother Pharmacol 33:450-454, 1994
13. Janus N, Thariat J, Boulanger H, et al: Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol 21:1395-1403, 2010
14. Haubitz M, Bohnenstengel F, Brunkhorst R, et al: Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int 61:1495-1501, 2002
15. Juma FD, Rogers HJ, Trounce JR: Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites. Eur J Clin Pharmacol 19:443-451, 1981
16. Breton G, Froissart M, Janus N, et al: Inappropriate drug use and mortality in communitydwelling elderly with impaired kidney function: The Three-City population-based study. Nephrol Dial Transplant 26:2852-2859, 2011
17. Dogan E, Izmirli M, Ceylan K, et al: Incidence of renal insufficiency in cancer patients. Adv Ther 22:357-362, 2005
18. Janus N, Launay-Vacher V, Byloos E, et al: Cancer and renal insufficiency results of the BIRMA study. Br J Cancer 103:1815-1821, 2010
19. O'Cearbhaill RE, Miller A, Muggia F, et al: Carboplatin dosing in the treatment of epithelial ovarian cancer (EOC): A Gynecologic Oncology Group (GOG) study. J Clin Oncol 30, 2012 (abstr 5041)
20. Raj GV, Iasonos A, Herr H, et al: Formulas calculating creatinine clearance are inadequate for determining eligibility for cisplatin-based chemotherapy in bladder cancer. J Clin Oncol 24:3095-3100, 2006
21. Berman N, Hostetter TH: Comparing the Cockcroft-Gault and MDRD equations for calculation of GFR and drug doses in the elderly. Nat Clin Pract Nephrol 3:644-645, 2007
22. Marx GM, Blake GM, Galani E, et al: Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol 15:291-295, 2004
23. Friedman JR, Norman DC, Yoshikawa TT: Correlation of estimated renal function parameters versus 24-hour creatinine clearance in ambulatory elderly. J Am Geriatr Soc 37:145-149, 1989
24. Nicoll SR, Sainsbury R, Bailey RR, et al: Assessment of creatinine clearance in healthy subjects over 65 years of age. Nephron 59:621-625, 1991
25. Smythe M, Hoffman J, Kizy K, et al: Estimating creatinine clearance in elderly patients with low serum creatinine concentrations. Am J Hosp Pharm 51:198-204, 1994
26. Lichtman SM: Call for changes in clinical trial reporting of older patients with cancer. J Clin Oncol 30:893-894, 2012
27. Lichtman SM: Clinical trial design in older adults with cancer-The need for new paradigms. J Geriatr Oncol 3:368-375, 2012
28. Wildiers H, Mauer M, Pallis A, et al: End points and trial design in geriatric oncology research: A joint European Organisation for Research and Treatment of Cancer-Alliance for Clinical Trials in Oncology-International Society of Geriatric Oncology position article. J Clin Oncol 31:3711-3718, 2013